Morbid ObesityPhase 4NCT07859163
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain
A Phase 4 study testing Semaglutide weekly injection in people with Morbid Obesity, run by General Committee of Teaching Hospitals and Institutes, Egypt at 1 site in Egypt.
Trial summary
Recurrent weight gain affects 15% to 40% of patients after metabolic and bariatric surgery (MBS). SG is the most performed operation worldwide, and long-term regain after SG is well documented. A 2026 international Delphi consensus has now standardized the definition. This trial uses that definition. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Morbid Obesity
- What is being tested?
- Semaglutide weekly injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- Oct 2026to Apr 2029
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- SG at least 2 years before screening.
- Recurrent weight gain meeting the international Delphi consensus definition. Operational entry threshold for this trial: regain of at least 20% of the maximal weight lost, measured from nadir.
- BMI of 35 kg/m² or more, or 30 kg/m² or more with at least one obesity-associated disease, and accepted for conversion to RYGB by the multidisciplinary team.
- Upper endoscopy and contrast imaging completed.
- Able to give written informed consent.
Who cannot join
- Anatomy. These patients need surgery regardless of drug response, so randomizing them is not ethical. They are operated outside the trial. This is the operational form of the rule: anatomical cause, direct surgery; no anatomical cause, eligible for the trial.
- Staple-line leak or gastric fistula.
- Sleeve stenosis or axial twist.
- Hiatal hernia larger than 3 cm.
- Los Angeles grade C or D esophagitis, or Barrett's esophagus.
- Drug and general safety
Show all 14Show fewer
- GLP-1 receptor agonist use within the last 6 months, or previous intolerance.
- History of pancreatitis.
- Personal or family history of medullary thyroid carcinoma or MEN2.
- Type 1 diabetes; eGFR below 30 mL/min/1.73 m²; active malignancy.
- Pregnancy, breastfeeding, or pregnancy plans during the study. Women of childbearing potential must use reliable contraception. Per current labeling and the 2026 Standards, obesity pharmacotherapy is stopped at least 2 months before any planned conception.
- Uncontrolled psychiatric disease or active substance use disorder.
- Current smoking, unless cessation is completed before surgery per unit policy.
- Any other anti-obesity medication within the last 3 months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
The surgical department of Medical Research Institute Hospital, Alexandria University
Alexandria, 21531
Mohamed Hany Ashour, Professor, MD, +201002600970, mohamed.ashour@alexu.edu.eg
Mohamed Hany Ashour, Professor, MD, mohamed.ashour@alexu.edu.eg
About this study
Official title: Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain: a Randomized, Double-blind, Placebo-controlled Trial
Recurrent weight gain affects 15% to 40% of patients after metabolic and bariatric surgery (MBS). SG is the most performed operation worldwide, and long-term regain after SG is well documented. A 2026 international Delphi consensus has now standardized the definition. This trial uses that definition. So does our companion trial, RESURGE.
We have two real treatments. Both work. Neither is enough. Conversion of SG to RYGB gives around 20% additional total weight loss at 12 months across all indications, and less when the indication is poor weight response rather than reflux. Drug therapy also works after MBS. Liraglutide beat placebo by about 8 percentage points in the BARI-OPTIMISE randomized trial. Semaglutide gives around 11% total weight loss and tirzepatide around 14% in pooled retrospective data, including specifically after SG. Most patients do not return to their nadir weight with either option alone.
Read more
The field is already comparing the two strategies, but only retrospectively. Two 2025 multicenter cohorts compared conversion against GLP-1 therapy after SG. These studies cannot control diet, exercise, supplementation, co-medication, or adherence. They cannot settle the question.
The societies agree on the pathway but admit the evidence is weak. The 2024 IFSO position statement and the 2026 ASMBS statement say the same thing: work up the anatomy first; operate when there is a structural problem; consider medical therapy when there is not; and consider combining drug therapy with revision. The 2024 IFSO international consensus goes further: with 92% agreement, it states that medications should generally be considered before revisional surgery for recurrent weight gain. Every one of those recommendations rests on consensus and retrospective data. None rests on a randomized trial. This protocol is that trial.
Read the detailed description
The biology says the combination should win. Revision restores restriction and corrects anatomy. It does not correct appetite biology. Patients with poor response after MBS show blunted satiety-hormone profiles, which is exactly what GLP-1 therapy replaces. The operation and the drug cover each other's weakness. They are complementary tools, not competitors.
Medical therapy alone has a durability problem. When the drug stops, weight returns. SURMOUNT-4 showed rapid regain after tirzepatide withdrawal, and meta-analysis confirms the pattern across agents. Surgery provides the durable base. The drug adds effect where it is needed most: around the revision. That is the logic of the sandwich.
The pre-operative phase has three jobs. It tests whether the patient tolerates and responds to the drug before we commit to a reoperation. It produces weight loss before revisional surgery, where technical difficulty and risk are higher than in primary surgery. And it gives strong medical responders a genuine chance to avoid the reoperation altogether.
Some patients on active drug will lose enough weight before surgery to step off the operating list. We expect this. It is not a flaw and it is not contamination. It is a pre-specified secondary endpoint. It is also the first randomized test of the advice the guidelines already give: try medical therapy first when the anatomy is normal. Patients whose anatomy forces surgery are not in this trial at all; they go straight to the operating room, as they should.
Every published combination series is confounded. Diet, exercise, supplements, other drugs, and adherence differ between patients and are rarely measured. This protocol standardizes all of them in both arms and measures them objectively. Section 8 lists each confounder and what we do about it.
- Conditions
- Morbid Obesity
- Being tested
- Semaglutide weekly injection, Placebo
- Keywords
- SANDWICH, Semaglutide, conversion of sleeve gastrectomy to Roux-en-Y gastric bypass, sleeve gastrectomy, Roux-en-Y gastric bypass, recurrent weight gain
- Medical subject headings
- Obesity, Morbid, Weight Gain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Semaglutide weekly injectionDrug
Weekly subcutaneous injections from identical, pharmacy-labelled pens. The active arm receives semaglutide 2.4 mg. Escalation: 0.25, 0.5, 1.0, 1.7, 2.4 mg at 4-week steps. If 2.4 mg is not tolerated, the patient stays on the highest tolerated dose of at least 1.0 mg. Patients who cannot tolerate 1.0 mg stop injections but stay in the trial and are analyzed in their arm.
PlaceboDrug
Weekly subcutaneous injections from identical, pharmacy-labelled pens. The placebo arm receives matched placebo. Escalation: 0.25, 0.5, 1.0, 1.7, 2.4 mg at 4-week steps. If 2.4 mg is not tolerated, the patient stays on the highest tolerated dose of at least 1.0 mg. Patients who cannot tolerate 1.0 mg stop injections but stay in the trial and are analyzed in their arm.
| Study group | Role | What they receive |
|---|---|---|
| GLP 1 | Active comparator | Semaglutide 2.4 mg weekly: 16 weeks before conversion, held 7 days before surgery, restarted 4 weeks after surgery, continued to 12 months after surgery. Receives: Drug: Semaglutide weekly injection |
| Placebo | Placebo comparator | Matched placebo on the identical schedule. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage total weight loss
Measured in kilograms at month 18 after randomization. Baseline is the randomization weight.
Measured: Baseline till 30 months
Secondary outcomes (12)
BMI change
Equation: BMI = weight (In kilograms) / [height (In meters)]^2
Measured: 0, 3, 6, 9, 12 months
change in HbA1c
An HbA1c level reflects your average blood sugar over the past two to three months, and any meaningful change typically takes at least 6 weeks to show because red blood cells live for about 3 months.
Normal: Below 5.7% Prediabetes: 5.7% to 6.4% Diabetes: 6.5% or higher
Measured: 0, 6, 12 months
systolic and diastolic blood pressure
Normal blood pressure is less than 120 mm Hg systolic and less than 80 mm Hg diastolic.
Systolic (Top Number): Measures the pressure in your arteries when your heart beats and contracts.
Diastolic (Bottom Number): Measures the pressure in your arteries when your heart rests between beats.
Normal: Less than 120 mm Hg systolic and less than 80 mm Hg diastolic. Elevated: 120-129 mm Hg systolic and less than 80 mm Hg diastolic. Stage 1 Hypertension (High Blood Pressure): 130-139 mm Hg systolic or 80-89 mm Hg diastolic.
Stage 2 Hypertension: 140 mm Hg or higher systolic, or 90 mm Hg or higher diastolic.
Hypertensive Crisis: Higher than 180 mm Hg systolic and/or higher than 120 mm Hg diastolic. This requires immediate emergency medical care
Measured: 0, 6, 12 months
total cholesterol, LDL, HDL, and triglycerides
Normal adult values for a lipid panel are measured in milligrams per deciliter (mg/dL):
Total Cholesterol: Below 200 mg/dL is desirable. (Borderline high is 200-239 mg/dL, and high is 240 mg/dL and above.) LDL ("Bad") Cholesterol: Below 100 mg/dL is optimal. (130-159 mg/dL is borderline high, and 160-189 mg/dL or higher is high.) HDL ("Good") Cholesterol: 60 mg/dL and higher is protective. Levels below 40 mg/dL for men or below 50 mg/dL for women are considered low.
Triglycerides: Below 150 mg/dL is normal. (Borderline high is 150-199 mg/dL, and high is 200-499 mg/dL.)
Measured: 0, 6, 12 months
Operative time
From the start till the end of the surgery measured in minutes
Measured: At the time or during surgery
Intraoperative adverse events
Adverse intraoperative events (AIEs) occur in approximately 3% to 7% of bariatric surgeries and increase the relative risk of overall postoperative complications by about 90%.
Organ Injuries: Unintentional lacerations or punctures to the liver, spleen, stomach, intestines, or major blood vessels during trocar placement or dissection.
Intraoperative Bleeding: Significant hemorrhage from staple lines, mesentery, or the abdominal wall requiring intervention or transfusion.
Anastomosis and Staple Line Issues: Leaks, bleeding, or technical difficulties during the creation of pouches or connections (such as in a Roux-en-Y Gastric Bypass), identified via intraoperative leak tests.
Equipment Malfunction: Failures involving laparoscopic staplers, cameras, insufflation systems, or energy devices.
Anesthesia-Related Events: Severe hemodynamic instability, difficult airway management, or allergic reactions linked to medications.
Measured: At the time or during surgery
30-day complications
The Clavien-Dindo Classification grades 30-day postoperative complications based on the level of medical or surgical therapy needed to treat them.
Grade I: Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions.
Grade II: Requiring pharmacological treatment with drugs other than those allowed for Grade I, including blood transfusions and total parenteral nutrition.
Grade III: Requiring surgical, endoscopic, or radiological intervention. Grade IIIa: Intervention not under general anesthesia. Grade IIIb: Intervention under general anesthesia. Grade IV: Life-threatening complication (including central nervous system complications) requiring intermediate care or intensive care unit (ICU) management.
Grade V: Death of a patient.
Measured: postoperative till 30 days
change in GerdQ score
A change in the GerdQ score reflects how gastroesophageal reflux disease (GERD) symptoms and their daily impact respond to treatment or evolve over time.
Range: The total score spans from 0 to 18. Diagnosis Threshold: A score of 8 or higher indicates a high likelihood of GERD.
Components: It evaluates four positive predictors (heartburn, regurgitation, sleep disturbance, and over-the-counter medication use) and two negative predictors (epigastric pain and nausea) over the past 7 days.
Decrease in Score: A lowering score (especially moving from ≥ 8 to < 8) typically indicates successful treatment response, reduced symptom frequency, and lower disease impact.
Increase or No Change: A rising score or a score that remains persistently above 8 suggests ongoing treatment failure, unmanaged symptom triggers, or disease progression.
Measured: 0, 6, 12 months
change in IWQOL-Lite-CT total and domain scores
The IWQOL-Lite-CT (Impact of Weight on Quality of Life-Lite Clinical Trials Version) score ranges from 0 to 100, where 100 represents the best possible quality of life and functioning (meaning zero weight-related impairment).
Total Score Range: 0-100 (higher = better quality of life) Domain/Composite Scores: 0-100 Raw scores are converted or transformed to a 0-100 scale for standard reporting.
Measured: 0, 6, 12 months
change in fat mass and lean soft tissue mass
(bioelectrical impedance analysis, standardized hydration instructions), with fat-free mass loss reported as a proportion of total weight change and hand-grip strength measured at weeks 0, 32, and 68, so that mass is interpreted together with function per the ESPEN/EASO sarcopenic-obesity framework and current meta-analytic evidence.
Measured: 0, 6, 12 months
Hand-grip strength
A hand grip strength test measures the maximum force of your hand and forearm muscles using a portable device called a handgrip dynamometer.
Position yourself: Sit up straight with your feet flat on the floor. Place your arm by your side with your elbow bent at a 90-degree angle and your wrist in a neutral position.
Hold the device: Adjust the handle so it fits comfortably in your hand. Squeeze hard: Squeeze the handles as hard as you can for about 3 to 5 seconds without moving your arm or resting the device against your body.
Repeat trials: Take three measurements for each hand, resting for 15 to 30 seconds between attempts. Use either the highest score or the average of the trials.
A normal hand grip strength score typically ranges from 40 to 56 kg (88 to 123 lbs) for adult men and 25 to 36 kg (55 to 79 lbs) for adult women aged 20-29.
Measured: 0, 6, 12 months
Safety of the drug phase
all adverse events, with events of special interest: pancreatitis, gallstones, severe gastrointestinal intolerance, hypoglycemia, dumping, aspiration at induction, venous thromboembolism, mortality.
Measured: Baseline till 30 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2026
- Study startOct 2026 (estimated)
- Primary completionApr 2029 (estimated)
- Study completionApr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Morbid ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Mohamed Hany Ashour, General Committee of Teaching Hospitals and Institutes, Egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07859163
- Sponsor's protocol ID
- SANDWICH Trial
- Status last verified
- Sep 2026
- First submitted
- 29 Sep 2026
- Last updated
- 5 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain: a Randomized, Double-blind, Placebo-controlled Trial
- ClinicalTrials.gov ID
- NCT07859163
- Acronym / sponsor ID
- SANDWICH Trial
- Conditions
- Morbid Obesity
- Keywords
- SANDWICH, Semaglutide, conversion of sleeve gastrectomy to Roux-en-Y gastric bypass, sleeve gastrectomy, Roux-en-Y gastric bypass, recurrent weight gain
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- General Committee of Teaching Hospitals and Institutes, EgyptOther government
- Study start
- Oct 2026 (estimated)
- Primary completion
- Apr 2029 (estimated)
- Study completion
- Apr 2029 (estimated)
- First posted
- 5 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recurrent weight gain affects 15% to 40% of patients after metabolic and bariatric surgery (MBS). SG is the most performed operation worldwide, and long-term regain after SG is well documented. A 2026 international Delphi consensus has now standardized the definition. This trial uses that definition. So does our companion trial, RESURGE.
We have two real treatments. Both work. Neither is enough. Conversion of SG to RYGB gives around 20% additional total weight loss at 12 months across all indications, and less when the indication is poor weight response rather than reflux. Drug therapy also works after MBS. Liraglutide beat placebo by about 8 percentage points in the BARI-OPTIMISE randomized trial. Semaglutide gives around 11% total weight loss and tirzepatide around 14% in pooled retrospective data, including specifically after SG. Most patients do not return to their nadir weight with either option alone.
The field is already comparing the two strategies, but only retrospectively. Two 2025 multicenter cohorts compared conversion against GLP-1 therapy after SG. These studies cannot control diet, exercise, supplementation, co-medication, or adherence. They cannot settle the question.
The societies agree on the pathway but admit the evidence is weak. The 2024 IFSO position statement and the 2026 ASMBS statement say the same thing: work up the anatomy first; operate when there is a structural problem; consider medical therapy when there is not; and consider combining drug therapy with revision. The 2024 IFSO international consensus goes further: with 92% agreement, it states that medications should generally be considered before revisional surgery for recurrent weight gain. Every one of those recommendations rests on consensus and retrospective data. None rests on a randomized trial. This protocol is that trial.
Detailed description
The biology says the combination should win. Revision restores restriction and corrects anatomy. It does not correct appetite biology. Patients with poor response after MBS show blunted satiety-hormone profiles, which is exactly what GLP-1 therapy replaces. The operation and the drug cover each other's weakness. They are complementary tools, not competitors.
Medical therapy alone has a durability problem. When the drug stops, weight returns. SURMOUNT-4 showed rapid regain after tirzepatide withdrawal, and meta-analysis confirms the pattern across agents. Surgery provides the durable base. The drug adds effect where it is needed most: around the revision. That is the logic of the sandwich.
The pre-operative phase has three jobs. It tests whether the patient tolerates and responds to the drug before we commit to a reoperation. It produces weight loss before revisional surgery, where technical difficulty and risk are higher than in primary surgery. And it gives strong medical responders a genuine chance to avoid the reoperation altogether.
Some patients on active drug will lose enough weight before surgery to step off the operating list. We expect this. It is not a flaw and it is not contamination. It is a pre-specified secondary endpoint. It is also the first randomized test of the advice the guidelines already give: try medical therapy first when the anatomy is normal. Patients whose anatomy forces surgery are not in this trial at all; they go straight to the operating room, as they should.
Every published combination series is confounded. Diet, exercise, supplements, other drugs, and adherence differ between patients and are rarely measured. This protocol standardizes all of them in both arms and measures them objectively. Section 8 lists each confounder and what we do about it.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| GLP 1 | Active comparator | Drug: Semaglutide weekly injectionSemaglutide 2.4 mg weekly: 16 weeks before conversion, held 7 days before surgery, restarted 4 weeks after surgery, continued to 12 months after surgery. |
| Placebo | Placebo comparator | Drug: PlaceboMatched placebo on the identical schedule. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- SG at least 2 years before screening.
- Recurrent weight gain meeting the international Delphi consensus definition. Operational entry threshold for this trial: regain of at least 20% of the maximal weight lost, measured from nadir.
- BMI of 35 kg/m² or more, or 30 kg/m² or more with at least one obesity-associated disease, and accepted for conversion to RYGB by the multidisciplinary team.
- Upper endoscopy and contrast imaging completed.
- Able to give written informed consent.
Key exclusion criteria (14 listed)
- Anatomy. These patients need surgery regardless of drug response, so randomizing them is not ethical. They are operated outside the trial. This is the operational form of the rule: anatomical cause, direct surgery; no anatomical cause, eligible for the trial.
- Drug and general safety
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Semaglutide weekly injectionWeekly subcutaneous injections from identical, pharmacy-labelled pens. The active arm receives semaglutide 2.4 mg. Escalation: 0.25, 0.5, 1.0, 1.7, 2.4 mg at 4-week steps. If 2.4 mg is not tolerated, the patient stays on the highest tolerated dose of at least 1.0 mg. Patients who cannot tolerate 1.0 mg stop injections but stay in the trial and are analyzed in their arm. | Drug | GLP 1 |
| PlaceboWeekly subcutaneous injections from identical, pharmacy-labelled pens. The placebo arm receives matched placebo. Escalation: 0.25, 0.5, 1.0, 1.7, 2.4 mg at 4-week steps. If 2.4 mg is not tolerated, the patient stays on the highest tolerated dose of at least 1.0 mg. Patients who cannot tolerate 1.0 mg stop injections but stay in the trial and are analyzed in their arm. | Drug | Placebo |
Primary outcome
Percentage total weight loss
Time frame: Baseline till 30 months
Measured in kilograms at month 18 after randomization. Baseline is the randomization weight.
12 secondary outcomes
BMI change
Time frame: 0, 3, 6, 9, 12 months
change in HbA1c
Time frame: 0, 6, 12 months
systolic and diastolic blood pressure
Time frame: 0, 6, 12 months
total cholesterol, LDL, HDL, and triglycerides
Time frame: 0, 6, 12 months
Operative time
Time frame: At the time or during surgery
Intraoperative adverse events
Time frame: At the time or during surgery
30-day complications
Time frame: postoperative till 30 days
change in GerdQ score
Time frame: 0, 6, 12 months
change in IWQOL-Lite-CT total and domain scores
Time frame: 0, 6, 12 months
change in fat mass and lean soft tissue mass
Time frame: 0, 6, 12 months
Hand-grip strength
Time frame: 0, 6, 12 months
Safety of the drug phase
Time frame: Baseline till 30 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2026.
- Individual participant dataSharing planned: Yes
Related trials for Morbid Obesity
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Not yet recruitingObservational study
Evaluating Metabolic Health in Individuals With Extreme Obesity
BMI>40
Enrolling by invitationObservational study
Bariatric Surgery Registry
Obesity, Morbid
Not yet recruitingObservational study
Serum Estradiol and Endometrial Thickness After Bariatric Surgery in Postmenopausal Women With Obesity
Obesity, Morbid, Postmenopause
Active, not recruiting
Mindfulness Based Eating Awareness Training for Bariatric Surgery Patients
Obesity, Morbid, Eating Disorder Symptom
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Semaglutide weekly injection in people with Morbid Obesity, run by General Committee of Teaching Hospitals and Institutes, Egypt at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed Hany Ashour, Professor, MD (+201002600970, mohamed.ashour@alexu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage total weight loss (time frame: Baseline till 30 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.